Pharma: Page 18
-
Andreas Rentz via Getty Images
Bayer details layoffs as company shake-up continues
The reduction of 1,500 roles in the first quarter is part of CEO Bill Anderson’s plan to shrink Bayer’s bureaucracy and “radically realign” its culture.
By Delilah Alvarado • May 14, 2024 -
deliormanli via Getty Images
Sponsored by Almac GroupPartnering for success: Choosing the right CDMO in pharma outsourcing
Explore the four most important qualities for choosing a dependable outsourcing partner in pharma.
May 13, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Daniel Tadevosyan via Getty Images
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
Interim data surpassed expectations, iTeos said. Bluebird bio, meanwhile, gave a fuller accounting of launch progress for its gene therapies Lygenia, Zynteglo and Skysona.
By BioPharma Dive staff • May 10, 2024 -
Maddie Meyer via Getty Images
FDA delays decision on Moderna RSV vaccine
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.
By Delilah Alvarado • May 10, 2024 -
Carsten Koall via Getty Images
Novavax gets a lifeline with Sanofi vaccine pact
Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.
By Ned Pagliarulo • May 10, 2024 -
Stock via Getty Images
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
Among the pipeline changes is a decision by Takeda to terminate studies in blood cancer of TAK-007, a CAR-NK therapy, and to pivot instead to autoimmune conditions.
By Ned Pagliarulo • Updated May 10, 2024 -
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive // Patent thicketsDrug patents protect pharma profits. Track when they’ll expire.
This database now covers the 50 best-selling pharmaceutical products and has been updated to reflect current patent expiry expectations.
By Jonathan Gardner • Updated April 9, 2025 -
Sean Gallup via Getty Images
AstraZeneca withdraws COVID-19 vaccine, citing declining demand
The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.
By Delilah Alvarado • May 8, 2024 -
Jacob Bell/BioPharma Dive
FDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug
After delaying an approval decision for Lilly’s donanemab, the agency now intends to hold an advisory committee meeting on June 10.
By Jacob Bell • May 7, 2024 -
Christopher Furlong via Getty Images
AstraZeneca ups stake in Cellectis in latest cell therapy bet
The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.
By Jonathan Gardner • May 6, 2024 -
PrathanChorruangsak via Getty Images
Sponsored by Worldwide Clinical TrialsMaximizing efficiency in translational medicine with an on-site pharmacy
The ability to modify drug formulations in real time and dosage strengths is crucial, while adhering to all regulatory standards and maintaining cGMP standards.
May 6, 2024 -
Mario Tama via Getty Images
Amgen shares soar as executives outline obesity drug push
The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.
By Jonathan Gardner • May 3, 2024 -
Why selling to Novartis made sense for Mariana
Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."
By Ned Pagliarulo • May 3, 2024 -
Scott Olson via Getty Images
Novo sees Wegovy sales dip on lower price, tight supply
First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.
By Jonathan Gardner • May 2, 2024 -
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
The $1 billion dollar acquisition will add to Novartis’ pipeline of the targeted radiation drugs, giving it a potential lung cancer treatment.
By Delilah Alvarado • May 2, 2024 -
Warren Little via Getty Images
GSK raises forecasts on strong vaccine, HIV drug sales
Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.
By Delilah Alvarado • May 1, 2024 -
Mario Tama via Getty Images
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.
By Ned Pagliarulo • May 1, 2024 -
jetcityimage via Getty Images
Lilly counts on manufacturing scale-up to unstick obesity drug supply
Increasing the production capacity for Zepbound and Mounjaro is “the most ambitious expansion plan in our company’s history,” said CEO David Ricks.
By Jonathan Gardner • April 30, 2024 -
jetcityimage via Getty Images
Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb
Supply continues to be tight, however, and the company anticipates further sales growth will be limited by how quickly it can add production capacity.
By Ned Pagliarulo • Updated April 30, 2024 -
Win McNamee via Getty Images
AbbVie tries to reassure investors on Humira biosimilar threat
Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.
By Jonathan Gardner • April 26, 2024 -
Christopher Furlong via Getty Images
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
By Jonathan Gardner • April 25, 2024 -
Permission granted by Bristol-Myers Squibb
Bristol Myers to cut 6% of workforce, trim drug pipeline
The layoffs will impact some 2,200 employees, the company said, as it repositions ahead of looming patent expirations for top-selling products.
By Ned Pagliarulo • Updated April 25, 2024 -
Permission granted by Biogen
Biogen sees ‘encouraging’ trends for postpartum depression drug
First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.
By Delilah Alvarado • April 24, 2024 -
William Walker/BioPharma Dive
Sponsored by Allucent[Podcast] Partner for Progress: Strategies for Biotech Success
In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness.
Updated June 3, 2024 -
Win McNamee via Getty Images
Former Bristol Myers CEO tapped as Novartis’ next board chair
Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.
By Delilah Alvarado • April 23, 2024
Previous
